Journal Watch · Frontiers in Immunology · 2026

Identification and validation of biomarkers related to mismatch repair for prognosis prediction in glioma.

Critically, we identify MCM8 as a novel and actionable biomarker that modulates TMZ sensitivity, offering a promising avenue for personalized treatment in glioma patients.

Feng J, Si Y, Han L et al.Frontiers in Immunology4 min readPharma relevance 85/100

DOI: 10.3389/fimmu.2026.1652739PMID: 42416056Study type: in-vitro / cell study

TL;DR

Critically, we identify MCM8 as a novel and actionable biomarker that modulates TMZ sensitivity, offering a promising avenue for personalized treatment in glioma patients.

Key findings

  • The validity of this model has been validated in the CGGA dataset.
  • Significant differences in immune infiltration, TME, and TMB scores were observed between risk groups.
  • Drug sensitivity analysis revealed distinct IC<sub>50</sub> profiles for chemotherapeutic agents between the groups.
  • Most importantly, <i>in vitro</i> experiments demonstrated that MCM8 overexpression increased glioma cell sensitivity to TMZ, while MCM8 knockdown decreased it, identifying MCM8 as a potential target for TMZ-based personalized therapy.<h4>Conclusion</h4>This study establishes a robust MMR-related prognostic model for glioma that effectively stratifies patients, predicts survival, and reflects distinct immune microenvironments.
  • Critically, we identify MCM8 as a novel and actionable biomarker that modulates TMZ sensitivity, offering a promising avenue for personalized treatment in glioma patients.

What they did

The model's performance was assessed using ROC curves, AUC, and Kaplan-Meier survival analysis. Immune cell infiltration was quantified using "CIBERSORT" and "QUANTISEQ". Immunotherapy potential was evaluated via TMB, TME, and TIDE scores. The half maximal inhibitory concentration (IC<sub>50</sub>) analyses were performed. <i>In vitro</i> validation involved MCM8 overexpression/knockdown in U251/LN229 glioma cells, followed by TMZ sensitivity testing via CCK-8 assays.<h4>Results</h4>An eight-MMR-related gene prognostic model (HMGB1, MCM8, MUTYH, PMS1, RNASEH2B, RNASEH2C, RPA3, TP73) was constructed. The risk score was an independent prognostic factor, with high-risk patients showing significantly poorer overall survival.

Full abstract (original)

Background: <h4>Background</h4>Gliomas are aggressive brain tumors with a dismal prognosis, and their development, progression, and responsiveness to treatment are all impacted by mismatch repair (MMR) deficiency. This work aimed to construct a predictive risk model based on MMR-related genes and confirm its clinical applicability, with a focus on identifying novel therapeutic targets.<h4>Methods</h4>Clinical and mRNA expression data from The Cancer Genome Atlas (TCGA) and The Chinese Glioma Genome Atlas (CGGA) glioma patients were analyzed. MMR-related genes were sourced from the Molecular Signatures Database (MSigDB). A risk score model was created using multivariate Cox regression and LASSO analysis. Patients were categorized into high- and low-risk groups based on the median risk score.

What they did: The model's performance was assessed using ROC curves, AUC, and Kaplan-Meier survival analysis. Immune cell infiltration was quantified using "CIBERSORT" and "QUANTISEQ". Immunotherapy potential was evaluated via TMB, TME, and TIDE scores. The half maximal inhibitory concentration (IC<sub>50</sub>) analyses were performed. <i>In vitro</i> validation involved MCM8 overexpression/knockdown in U251/LN229 glioma cells, followed by TMZ sensitivity testing via CCK-8 assays.<h4>Results</h4>An eight-MMR-related gene prognostic model (HMGB1, MCM8, MUTYH, PMS1, RNASEH2B, RNASEH2C, RPA3, TP73) was constructed. The risk score was an independent prognostic factor, with high-risk patients showing significantly poorer overall survival.

Results & conclusions: The validity of this model has been validated in the CGGA dataset. Significant differences in immune infiltration, TME, and TMB scores were observed between risk groups. Drug sensitivity analysis revealed distinct IC<sub>50</sub> profiles for chemotherapeutic agents between the groups. Most importantly, <i>in vitro</i> experiments demonstrated that MCM8 overexpression increased glioma cell sensitivity to TMZ, while MCM8 knockdown decreased it, identifying MCM8 as a potential target for TMZ-based personalized therapy.<h4>Conclusion</h4>This study establishes a robust MMR-related prognostic model for glioma that effectively stratifies patients, predicts survival, and reflects distinct immune microenvironments. Critically, we identify MCM8 as a novel and actionable biomarker that modulates TMZ sensitivity, offering a promising avenue for personalized treatment in glioma patients.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1652739 · PubMed 42416056.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

Critically, we identify MCM8 as a novel and actionable biomarker that modulates TMZ sensitivity, offering a promising avenue for personalized treatment in glioma patients.

What type of study is this?

It is a in-vitro / cell study, published in Frontiers in Immunology in 2026. The model's performance was assessed using ROC curves, AUC, and Kaplan-Meier survival analysis.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1652739. PubMed ID: 42416056. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Feng J, Si Y, Han L et al.. Identification and validation of biomarkers related to mismatch repair for prognosis prediction in glioma.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1652739.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/identification-and-validation-of-biomarkers-related-to-mismatch-repair-f-652739/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides